Chronic myeloid leukemia: the cutting-edge evidence and things we should know.

The prognosis of patients with chronic myeloid leukemia has dramatically improved along with the progress of therapy. However, some concerns remain unresolved, and new treatment strategies have been implemented recently. In this Progress in Hematology corner, the following four issues are presented and discussed: (1) Guidelines for the treatment of chronic myeloid leukemia from the NCCN and ELN: Differences and similarities; (2) Asciminib as a third-line option in chronic myeloid leukemia; (3) Dose optimization of tyrosine kinase inhibitor therapy in chronic myeloid leukemia; and (4) Genetic landscape of chronic myeloid leukemia. All these review articles will provide critical information for hematologists and let us know things we should learn in order to treat patients with this disease adequately.